Subscribe to:
POZ magazine E-newsletters
POZ Personals Sign In / Join
Username:
Password:
African American Hub News
 

Back to home » News & Views » Treatment News


 

January 2009
December 2008
November 2008
October 2008
September 2008
August 2008
July 2008
June 2008
May 2008
April 2008
March 2008
February 2008
January 2008
December 2007
November 2007
October 2007
September 2007
August 2007
July 2007
June 2007
May 2007
April 2007
March 2007
February 2007


emailrssprint

June 6, 2008

A New Improved HIV Tropism Test

A new version of the Trofile HIV tropism test is far more effective than the original assay at determining whether a person will likely respond to the entry inhibitor Selzentry (maraviroc), according to a press release issued by Monogram Biosciences. The test is now available to anyone who needs tropism testing.

Tropism testing is necessary if Selzentry is to be included in an antiretroviral regimen and is used to determine which coreceptor on CD4 cells a person’s HIV is using: CCR5, CXCR4 or both (dual/mixed). Selzentry is effective against CCR5-using HIV only, not dual/mixed or CXCR4-using virus.

The original Trofile test, which became available with the approval of Selzentry last August, was only sensitive enough to accurately detect dual/mixed virus if it made up more than 10 percent of the HIV population in a person’s blood sample. This meant that a significant number of people were at risk of receiving a test result indicating that Selzentry should work well, only to quickly experience treatment failure. The new enhanced Trofile test is 100 percent sensitive at detecting dual/mixed virus making up as little as 0.3 percent of the HIV population in a blood sample.

A representative for Monogram stated that there will be no increase in price over the older Trofile test.

NEW! Scroll down to comment on this story.

emailrssprint

Name:

(will display; 2-50 characters)

Email:

(will NOT display)

City:

(will display; optional)

Comment (500 characters left):

(Note: The POZ team review all comments before they are posted. Please do not include either ":" or "@" in your comment.)

| Posting Rules

Previous Comments:

  comments 1 - 2 (of 2 total)    

Brian Greul, Houston, 2008-06-10 14:17:31
Schering Plough is currently doing Phase III trials for vicriviroc (their entry inhibitor) and they will do the trofile assay as part of the screening. They have trials for both treatment naive and treatment experienced people.

Jauri, SF, 2008-06-09 12:29:27
I was really looking forward to get this test and try Selzentry but unfortunately i cannot afford the $2K price for it , the good news is that the treatments available are really good as well , I'm newly infected and drug naive, but for people with resistance issues this can be a miracle drug , i really hope it works for the best as a new class , we are very lucky to have this advanced new approaches , good luck to all .

comments 1 - 2 (of 2 total)    


[Go to top]


Get Answers
What to do if you've just been diagnosed
How to find a support system
Things you should know before starting treatment
How to handle side effects and other concerns
How to tell someone you have HIV/AIDS

Blogs by African-Americans
Antonia
Felipe
JC Jeanette
Pinnace
Kate
Ferguson

Read the blogs
Overheard in the Forums
"I'm HIV positive and diabetic (as well as have high cholesterol) and some of my meds specify taking them with 'high fat foods' which I have to do twice a day. I've eaten as healthy as possible, but when it comes to high fat foods, I am in a quandary...about what to eat sometimes..."

from Nutrition & HIV


Join the forums

Real Health Poll
Question: Do you know anyone who successfully quit smoking?
Yes
No

Smart + Strong Network
POZ Magazine
POZ Personals
POZ Mentor
POZ ASO Directory
AIDSmeds
Real Health Magazine
TuSalud Magazine
ComboCards
Rx Info Cards
Also visit POZ on...
Facebook

MySpace

YouTube

[ about Smart + Strong | about POZ | POZ advisory board | partner links | advertise/contact us | site map]
© 2009 Smart + Strong. All Rights Reserved. Terms of use and Your privacy